Ondine Biomedical's Steriwave Shown Effective Against Deadly Mucor Fungus
Why we think this is neutral
This RNS announcement provides positive news about the efficacy of Ondine Biomedical's Steriwave technology against the Mucor fungus, which can be a serious threat to immunocompromised patients. However, as this is a general business update rather than a specific financial or operational announcement, I have assigned a neutral sentiment score.
Key Points
- UCL researchers present data showing Steriwave photodisinfection is effective against Mucor fungus
- Mucor fungal infections pose a serious risk to immunocompromised patients, with high mortality rates
- Steriwave was able to completely inhibit Mucor growth in laboratory tests
- Findings point to potential for combined topical and systemic approach to treating Mucor infections
Summary
Ondine Biomedical Inc. (AIM: OBI) has announced new data from University College London (UCL), demonstrating the potent efficacy of the company's Steriwave® photodisinfection technology against the often-lethal fungus Mucor. The findings were presented at the 19th World Congress of the International Photodynamic Association in Shanghai, China. This represents a significant development, as Mucor fungal infections pose a serious threat to immunocompromised patients, with mortality rates often exceeding 50%. The research showed that Steriwave was able to completely inhibit the growth of Mucor in vitro, with potential for a combined topical and systemic approach to treatment.